Roche said Monday that the US Food and Drug Administration has approved the company's Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and Ventana HER2 Dual ISH DNA Probe Cocktail tests, clearing them for identifying HER2-positive metastatic breast cancer (mBC) patients who may be eligible for treatment with AstraZeneca's Enhertu (trastuzumab deruxtecan).

Natera said Friday that it is collaborating with oncology research firm Medica Scientia Innovation Research (MEDSIR) on the MiRaDoR breast cancer trial for hormone receptor-positive, HER2-negative breast cancer.

Original from: genomeweb Contract research organization Inotiv said Thursday that it has partnered with Lithuanian multiomics data analysis firm Vugene on artificial intelligence-assisted drug discovery...

I. Health Resources 1. Total Number of Medical and Health Institutions By the end of 2024, the total number of medical and health institutions nationwide reached 1,093,551, an increase of 22,766 compared t..

Diagnostics firm TrilliumBio said Tuesday that it is collaborating with Oncobit to offer the Swiss company's uveal melanoma monitoring assay in the US.

German diagnostic startup Amplifold said Wednesday that it has raised €5 million ($5.8 million) in an oversubscribed seed financing round.

Roche announced Tuesday that its PCR-based test for vaginitis has received CE marking. The test is now available in countries accepting the designation.

Molecular diagnostics firm BillionToOne reported after the close of the market on Tuesday that its Q3 2025 revenues more than doubled year over year.

3.4 Assembly Line Trend With the in-depth study of the hemostasis and thrombosis, the hemostasis and coagulation testing has become increasingly important. With the increasingly abundant coagulation test items, ..

Pillar Biosciences and AstraZeneca said Monday that they are expanding their collaboration on liquid biopsy testing to include China.

The Global Health Innovative Technology (GHIT) Fund said Monday that it has invested ¥70 million ($460,000) in the development of a prototype molecular assay to detect mpox.

Paradigm Health announced last Thursday that it acquired Flatiron Health's clinical research business, establishing a multiyear collaboration between the two companies.

Natera announced last Friday that it has acquired cancer diagnostic firm Foresight Diagnostics for $275 million upfront.

1. Roche Diagnostics Launches Its First China-Manufactured Real-Time Fluorescent Quantitative PCR Instrument LC PRO On December 3, 2025, at the first "Sino-Swiss Innovation Day" co-hosted by the Swiss Chamber of..

Original from: genomeweb Swedish diagnostics firm Devyser said Thursday that its next-generation sequencing-based test for stem cell transplantation monitoring has received regulatory approval in Canada...

Shanghai, China ¡ª December 2, 2025 £ü Agilent Technologies Inc. (NYSE: A) today held a ribbon-cutting ceremony at the Shanghai Waigaoqiao New Development Park to celebrate the 30th anniversary of the Agilent Shanghai..

Original from: genomeweb Scout Health announced Wednesday that it has been awarded up to $6 million in funding support from the antimicrobial resistance nonprofit CARB-X. The firm plans to use the fundin..

Original from: genomeweb As part of its strategic expansion into precision dermatology, Castle Biosciences recently introduced a new assay to guide systemic treatment decision making for the immune-drive..

On December 2, 2025, Merck announced that Rogier Janssens will officially assume the role of President of Merck China starting February 1, 2026. Over its 92 years in the Chinese market, Merck has remaine..

Diagnostics firm IdentifySensors Biologics has recently demonstrated proof of concept for the use of its electrochemical sensor-based diagnostic platform Check4 for cancer testing and is now moving closer to commercialization of the platform and related tests.